NCT05271318View on ClinicalTrials.gov

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

March 31, 2027

Study Completion Date

August 31, 2027

Conditions
Platinum-refractory Ovarian CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaPlatinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or CisplatinPlatinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or CisplatinPlatinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Interventions
BIOLOGICAL

TILT-123

Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123

BIOLOGICAL

pembrolizumab

pembrolizumab, a monoclonal antibody binding PD-1

DRUG

pegylated liposomal doxorubicin

Pegylated Liposomal Doxorubicin is a chemotherapy and a pegylated liposomal form of the anthracycline topoisomerase inhibitor, doxorubicin.

Trial Locations (4)

10075

RECRUITING

Northwell Heatlh/Lenox Hill Hospital, New York

44718

RECRUITING

Gabrail Cancer and Research Center, Canton

55905

RECRUITING

Mayo Clinic, Rochester

00180

ACTIVE_NOT_RECRUITING

Docrates Cancer Center, Helsinki

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

TILT Biotherapeutics Ltd.

INDUSTRY